This article only represents the author's own views.
Having tried one remedy without success, drug developer Xuanzhu Biopharm is seeking another solution for its financial troubles.
The company has filed to list its shares on the Hong Kong Stock Exchange, just six months after giving up an attempt to join Shanghai’s STAR Market, as it looks for ways to finance ongoing work on new drugs for cancer, digestive ailments and liver disease.
您已閱讀7%（436字），剩餘93%（5446字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。